Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
615.97B
Market cap615.97B
Price-Earnings ratio
38.77
Price-Earnings ratio38.77
Dividend yield
2.07%
Dividend yield2.07%
Average volume
8.10M
Average volume8.10M
High today
$253.88
High today$253.88
Low today
$253.05
Low today$253.05
Open price
$255.00
Open price$255.00
Volume
15.40K
Volume15.40K
52 Week high
$281.07
52 Week high$281.07
52 Week low
$184.66
52 Week low$184.66

Stock Snapshot

With a market cap of 615.97B, Johnson & Johnson(JNJ) trades at $253.05. The stock has a price-to-earnings ratio of 38.77 and currently yields dividends of 2.07%.

As of 2026-10-19, Johnson & Johnson(JNJ) stock has fluctuated between $253.05 and $253.88. The current price stands at $253.05, placing the stock 0.0% above today's low and -0.3% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 15.4K, compared to an average daily volume of 8.1M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $281.07 and a 52-week low of $184.66.

JNJ News

TipRanks 24m
Johnson & Johnson reports results from Phase 3 FUZION study

Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA, or guselkumab, maintained or improved fistula remission through 48 w...

24/7 Wall St. 1h
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead

Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well ab...

Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead
Simply Wall St 7h
What Does Johnson & Johnson News Mean For Its Growth Case?

Johnson & Johnson (NYSE: JNJ) received a positive CHMP opinion to extend TALVEY talquetamab use in relapsed or refractory multiple myeloma in Europe. The firm...

What Does Johnson & Johnson News Mean For Its Growth Case?

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

New York Times 13h
Jim Nantz needs ice pack after football punch mishap with J.J. Watt: ‘My wrist is broken’ - The New York Times

...

Jim Nantz needs ice pack after football punch mishap with J.J. Watt: ‘My wrist is broken’ - The New York Times
The Motley Fool 2d
Should You Invest in This Dividend King on the Dip?

Earnings season is underway, and it has already made some winners and losers. One company that seems to be in the latter category is Johnson & Johnson (JNJ +0.9...

Should You Invest in This Dividend King on the Dip?
24/7 Wall St. 2d
Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage

Investing Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage Raising dividends through two recessions takes more than a g...

Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage
The Motley Fool 2d
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare remains a cornerstone for long-term investors, but choosing between a pure-play drugmaker and a diversified conglomerate is difficult. Is Bristol-Mye...

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool 3d
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Oct. 13, 2026, Johnson & Johnson (JNJ +0.79%) raised its full-year sales outlook after operational revenue g...

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
Seeking Alpha 3d
Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more

This week's dividend activity included increased payouts from Interactive Brokers Group (IBKR) and Citizens Financial Group (CFG) as well as declarations from J...

Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more
Simply Wall St 3d
How Investors May Respond To J&J Raised 2026 Guidance

Johnson & Johnson raised its full year 2026 guidance after reporting higher sales from its Innovative Medicine segment, backed by TREMFYA long term Crohn's dise...

How Investors May Respond To J&J Raised 2026 Guidance

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.